Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 6, pp 16–18 | Cite as

Diagnostic Developments

News & View


  1. 1.
    Epigenomics. Epigenomics AG validates DNA methylation test as predictor of disease recurrence in breast cancer patients. Media release: 17 May 2005Google Scholar
  2. 2.
    European Pharmaceuticals. Epigenomics: Latest breast cancer marker data as expected. Lehman Brothers Equity Research (2005)Google Scholar
  3. 3.
    Nanogen. Study using Nanogen assay confirms NT-proBNP to have utility as predictor of mortality in patients with severe congestive heart failure. Media release: 8 Jun 2005Google Scholar
  4. 4.
    Stanton E, Hansen M, Wijeysundera HC, et al. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart Fail 2005; 7 (4): 557–65PubMedCrossRefGoogle Scholar
  5. 5.
    Loyola University Health System. Loyola researchers discover congestive heart failure biological marker which speeds diagnosis, treatment. Media release: 7 Jun 2005Google Scholar
  6. 6.
    National Institute of General Medical Sciences. Genetic variation alters response to common anti-clotting drug. Media Release: 2 Jun 2005Google Scholar
  7. 7.
    EurekAlert. Phase I study examines biomarkers for response to erlotinib in glioma. Media release: 14 Jun 2005Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations